Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Investor Presentation (September 2008)

47 slides from Neurocrine Biosciences's investor presentation, Sep 25, 2008

  1. Slide 1: A Pipeline of Website Presentation 9/25/08

    A Pipeline of Website Presentation 9/25/08

  2. Slide 2: Forward-looking risk statement

    This presentation includes early and late stage clinical data and projections based thereon that involve a number of risks and uncertainties. These risks include the specific risk that the clinical development of the products discussed will not successfully proceed to later stage clinical trials or

  3. Slide 3: Pipeline

    Pipeline Products Indication Preclinical Phase 1 Phase 2 Phase 3 Elagolix Endometriosis Elagolix Benign Prostatic Hyperplasia CRF1 Antagonist Anxiety/Depression (561679) CRF1 Antagonist Irritable Bowel Syndrome (IBS) (876008) CRF1 Antagonist (586529) Anxiety/Depression CRF2 Peptide Agonist Cardiovas

  4. Slide 4: GnRH Program

    GnRH Program Orally Available, Nonpeptide Antagonists A Pipeline of Website Presentation 9/25/08

  5. Slide 5: Nonpeptide GnRH Antagonists First in Class Opportunity

    Nonpeptide GnRH Antagonists First in Class Opportunity Administration • Ease of Use • Oral dosing • Flexible dosing Women Women’s’s Men ’s Men’s Health GnRH Antagonist Health Efficacy • No flare effect • Quick onset of action A Pipeline of Website Presentation 9/25/08

  6. Slide 6: GnRH is the Central Regulator of Reproductive Endocrine System

    GnRH is the Central Regulator of Reproductive Endocrine System in Men and Women Clinical Applications of Hypothalamic-Pituitary-Gonadal Axis GnRH Analogues Hypothalamus Prostate Prostate Clinical Practice ART ART Endometriosis Cancer Cancer Optic GnRH Endometriosis Chiasma Breast Precocious Uterine

  7. Slide 7: U.S. Endometriosis Market

    U.S. Endometriosis Market Large, clinically significant patient base Many women of child …and symptoms are primarily bearing age have perceived as moderate or endometriosis… severe by those diagnosed… 8 7 23% 6MM 6 5 Millions 4 3 2 1 77% 0 N = 62,481 Prevalence in Mild Moderate/Severe general popula

  8. Slide 8: Endometriosis Treatment Options

    Endometriosis Treatment Options Option Issues Wait for menopause It could be a while… NSAIDS (e.g. advil) Insufficient pain relief Oral Contraceptives (OCPs) Insufficient pain relief May help get pregnant, but Laparascopic ablation typically recurs Hysterectomy/remove ovaries Irrevocable decision (s

  9. Slide 9: Elagolix Clinical Trials as of September 2008

    Elagolix Clinical Trials as of September 2008 Total Subjects on Study Description Study Number Subjects 56418 Ph I SD / MD, female NBI-56418-0301 55 45 Ph I Site absorption, male NBI-56418-0401 6 6 Ph I SD, male NBI-56418-0402 8 8 Ph I Formulation, relative PK, male NBI-56418-0404 11 11 Ph I 6-wk, f

  10. Slide 10: Key Efficacy Endpoints 3-Month 501 & 504 Studies

    Key Efficacy Endpoints 3-Month 501 & 504 Studies: Week 12 Placebo Elagolix Study Study Study Study Study Study 0501 0504 0501 0504 0501 0504 75 mg 50 mg 150 mg 100 mg qd bid qd bid Endpoint Statistic (n=28) (n=20) (n=25) (n=21) (n=23) (n=24) CFB CPSSS Mean -3.7 -4.5 -3.8 -4.4 -5.2 -5.9 Baseline~8 CF

  11. Slide 11: Safety Assessment 501 & 504 Studies

    Safety Assessment 501 & 504 Studies 12 Weeks of Treatment Placebo Elagolix Study Study Study Study Study Study 0501 0504 0501 0504 0501 0504 75 mg 50 mg 150 mg 100 mg qd bid qd bid (n=28) (n=20) (n=25) (n=21) (n=23) (n=24) Discontinuation due to AE 4% 0% 20% 9% 4% 8% Overall AE Incidence 86% 85% 84%

  12. Slide 12: NBI-56418-0603 Top-line Results After 6-Month Treatment

    NBI-56418-0603 Top-line Results After 6-Month Treatment September 2008 A Pipeline of Website Presentation 9/25/08

  13. Slide 13: Target Product Profile Elagolix - Endometriosis

    Target Product Profile Elagolix - Endometriosis Characteristic Ideal Profile Indication The management of pain associated with endometriosis Duration 6 months with multiple re‐treatments • CPSSS: mean ↓ ≥ 5 • VAS: mean ↓ ≥ 20 Efficacy • Rapid onset < 1 month • Improvement in EHP‐5 (QoL) • No active

  14. Slide 14: Petal Study Design

    Petal Study Design A Pipeline of Website Presentation 9/25/08

  15. Slide 15: Recruitment and Baseline Characteristics

    Recruitment and Baseline Characteristics Recruitment Inquiries to Call Center Referred to Site Total number 8022 3393 Characteristic Elagolix 150 mg qd Elagolix 75 mg bid DMPA SC n=84 n=84 n=84 mean (SD) mean (SD) mean (SD) Age 32.4 (7.5) 31.4 (6.1) 31.6 (0.4) CPSSS total 9.2 (2.0) 9.0 (2.0) 9.2 (2.

  16. Slide 16: Primary Endpoint – Bone Mineral Density

    Primary Endpoint – Bone Mineral Density Pre-specified endpoint : DXA % change from baseline to Month 6 Lower bound of 95% CI to show no greater loss than -2.2% A Pipeline of Website Presentation 9/25/08

  17. Slide 17: Study Successful at Primary Endpoint

    Study Successful at Primary Endpoint LS Mean and 95% Confidence Interval A Pipeline of Website Presentation 9/25/08

  18. Slide 18: BMD % Change From Baseline at Month 6

    BMD % Change From Baseline at Month 6 Elagolix 150 mg qd Elagolix 75 mg bid DMPA-SC Femur n=56 n=63 n=51 LS Mean % -0.4732 -0.9940 -1.2891 95% CI % -0.9645, 0.0181 -1.4572, -0.5308 -1.8039, -0.7743 Elagolix 150 mg qd Elagolix 75 mg bid DMPA-SC Spine n=55 n=62 n=50 LS Mean % -0.1135 -1.3045 -0.9914 9

  19. Slide 19: Elagolix Effects on Bone Compare Favorably

    Elagolix Effects on Bone Compare Favorably Women 20-45 years of age Duration of Change in Treatment or Treatment/Condition Reference Spine BMD Observation (months) Leuprolide depot Agarwal, 1998 (GnRH agonist) for -4 to -10% 6 (review of multiple studies) endometriosis -1.2% 6 Crosignani et al, 2006

  20. Slide 20: Elagolix is Safe and Well Tolerated

    Elagolix is Safe and Well Tolerated Outcome Elagolix 150 mg qd Elagolix 75 mg bid DMPA-SC Completed 6-month Rx 67% 73% 61% Deaths 0 0 0 Discontinued due to SAE 0 0 2.4% Reported any AE 79% 81% 79% Discontinued due to AE 5% 7% 16% Adverse Event Elagolix 150 mg qd Elagolix 75 mg bid DMPA-SC >10% n (%)

  21. Slide 21: Hot Flashes

    Hot Flashes Comparable rate of hot flashes during 1 month of screening and 6 months of treatment Elagolix 150 mg Elagolix 75 mg Statistic DMPA SC qd bid During Screening n=84 n=84 n=84 Mean #/day (SD) 0.248 (0.453) 0.321 (1.106) 0.295 (0.787) Median #/day 0.000 0.000 0.000 During Treatment n=83 n=84

  22. Slide 22: Reduction in Vaginal Bleeding

    Reduction in Vaginal Bleeding Mean (SD)% of Days With Any Bleeding 60 Screening — Reduction in vaginal Treatment bleeding reflects 50 pharmacological effect of 40 treatments — DMPA is associated with 30 amenorrhea and 20 persistent spotting — Elagolix is associated with 10 decrease in menses or 0 am

  23. Slide 23: Reasons for Discontinuation During Treatment

    Reasons for Discontinuation During Treatment PETAL Study Preliminary Data Prior to Unblinding Reason for Elagolix 150 mg qd Elagolix 75 mg bid DMPA-SC Total Discontinuation n=84 n=84 n=84 n=252 n (%) n (%) n (%) n (%) Adverse event 4 (4.8) 6 (7.1) 13 (15.5) 23 (9.1) Protocol deviation 2 (2.4) 0 (0)

  24. Slide 24: Secondary Endpoints

    Secondary Endpoints Significant Improvement in Endometriosis Symptoms CPSSS and VAS A Pipeline of Website Presentation 9/25/08

  25. Slide 25: Clinically Meaningful and Statistically Significant Change from Baseline

    Clinically Meaningful and Statistically Significant Change from Baseline Secondary endpoints p<0.0001 LS Mean* Score Reduction at Month 6 Mean Score Elagolix Elagolix DMPA-SC Efficacy Assessment at Baseline 150 mg qd 75 mg bid 104 mg n=252 n=54 n=63 n=48 CPSSS Total 9.1 -5.5 -5.2 -5.3 Dysmenorrhea 2

  26. Slide 26: Significant Improvement in Total CPSSS

    Significant Improvement in Total CPSSS (Mean±SEM Change From Baseline) A Pipeline of Website Presentation 9/25/08

  27. Slide 27: Significant Improvement in Monthly Peak VAS

    Significant Improvement in Monthly Peak VAS A Pipeline of Website Presentation 9/25/08

  28. Slide 28: Petal Study Successful

    Petal Study Successful Pain reduction without bone loss ¾ Primary endpoint met – Lower bound of 95%CI did not exceed -2.2% change from baseline for either spine or femur bone mineral density – Data support selection of once daily dosing in 702 and 703 trials ¾ Secondary endpoints met – Significant r

  29. Slide 29: Elagolix Achieves Estradiol Suppression into Target Range

    Elagolix Achieves Estradiol Suppression into Target Range Median Estradiol at Week 24 (pg/mL) Elagolix 150 mg qd Elagolix 75 mg bid n=49 n=56 45.3 29.3 ¾ Hormone Data – Individual patient-level data remains blinded – Median values above reflect preliminary per protocol data set (i.e., all subjects w

  30. Slide 30: Additional Data Analyses

    Additional Data Analyses ¾ Additional analyses are contingent upon full unblinding of individual patient data and completion of quality control processes – Individual adverse events – Clinical lab values ¾ Pharmacometrics and PK/PD Modeling • Elagolix exposure, estradiol, BMD • Elagolix exposure, es

  31. Slide 31: Target Product Profile Elagolix - Endometriosis

    Target Product Profile Elagolix - Endometriosis Characteristic Ideal Profile Indication 9The management of pain associated with endometriosis Duration 96 months with multiple re‐treatments 9CPSSS: mean ↓ ≥ 5 9VAS: mean ↓ ≥ 20 Efficacy 9Rapid onset < 1 month 9Improvement in EHP‐5 (QoL) 9No active man

  32. Slide 32: Clinical Development 2008-09

    Clinical Development 2008-09 Elagolix Study Phase Output Timing 0702 Assess placebo run-in, revised Dose confirmation in PhIIb endpoints and DXA assessed at endometriosis (150mg qd + 250 Fully Enrolled higher exposure; mg qd) • topline data (1H09) 0703 As with 0702 plus active comparator Comparison

  33. Slide 33: Multiple Markets - Multiple Compounds

    Multiple Markets - Multiple Compounds Women’s Health Men’s Health Gynecology Gynecology Oncology Urology • Endometriosis •Uterine Fibroids • Breast Cancer • Benign Prostatic • Prostate Cancer Hypertrophy (BPH) First Second Third Elagolix “Phase 2b” Primary Indications Back-Up “Development Candidate”

  34. Slide 34: Elagolix Intellectual Property

    Elagolix Intellectual Property 5 Issued U.S. Patents covering: – elagolix composition of matter – pharmaceutical composition – methods of using elagolix Last composition of matter patent expires 2024 (not including patent term extension) Corresponding Foreign Applications pending or issued (expiring

  35. Slide 35: CRF Receptor Antagonists

    CRF Receptor Antagonists A Pipeline of Website Presentation 9/25/08

  36. Slide 36: CRF Antagonists: Current Status of NBI / GSK Compounds

    CRF Antagonists Current Status of NBI / GSK Compounds 2006 2007 2008 2009 Phase I Phase II Compound 876008 Phase I POC IBS Ongoing Compound 561679 Phase I Phase II Depression Novel chemotype and Studies PoC pharmacologic profile Start mid 2008 Multi-dose study complete Phase I Depression Compound 58

  37. Slide 37: Urocortin 2 for Congestive Heart Failure

    Urocortin 2 for Urocortin 2 Congestive Congestive Heart Failure (CHF) Heart Failure (CHF) A Pipeline of Website Presentation 9/25/08

  38. Slide 38: Preclinical Research Provides Insights into Urocortin 2 Action

    Preclinical Research Provides Insights into Urocortin 2 Action ¾ Provides acute and sustained afterload reduction due to vasodilatory action and reduction of left ventricle size ¾ Provides an improvement in myocardial relaxation and improves diastolic filling ¾ Provides enhanced myocardial inotropis

  39. Slide 39: Systemic Vascular Resistance

    Impact on Peripheral Resistance 80 Mean Arterial Pressure 60 Mean Arterial Blood Pressure: Dose-proportional decrease in mean (mm Hg) 40 arterial pressure 20 0 Predose 1 hr Infusion 4 hr Postdose Placebo Single‐blinded, placebo controlled, 25 μg UCN2 dose‐escalation study; 1 hr dosing 1800 with 2 we

  40. Slide 40: Pressure Rate Product

    Improved Cardiac Output and Less Work 8 Cardiac Output: Cardiac Output (L / min) Dose-proportional improvement of 6 Caridac Output in stable CHF 4 patients (up to 50% increase) 2 0 Predose 1 hr Infusion 4 hr Placebo Single‐blinded, placebo controlled, Postdose 25 μg UCN2 dose‐escalation study; 1 hr

  41. Slide 41: Preclinical Overview

    Preclinical Overview ¾ Safety Pharmacology (ICH compliant) — CNS Battery — Cardiopulmonary — Cardiovascular ¾ Preclinical Toxicology — Single dose studies –MTD ¾ Genotoxicity (all negative) — AMES — Mouse Lymphoma — Rat Micronucleus A Pipeline of Website Presentation 9/25/08

  42. Slide 42: Urocortin 2 Summary of Results to Date

    Urocortin 2 Summary of Results to Date ¾ Urocortin 2 represents a First in Class opportunity for the treatment of acutely decompensated heart failure (ADHF) – Novel mechanism of action – Multiple physiological actions ¾ Intravenous infusion of Urocortin 2 in stable CHF subjects produces – Rapid and

  43. Slide 43: R&D Capabilities

    Urocortin 2 for R&D Congestive Capabilities Heart Failure (CHF) A Pipeline of Website Presentation 9/25/08

  44. Slide 44: Neurocrine Capabilities: R & D

    Neurocrine Capabilities: R & D Discovery Research Preclinical Development Clinical Development A Pipeline of Website Presentation 9/25/08

  45. Slide 45: Research Technology

    Research Technology Real Time Data Integration in Drug Discovery ¾ Automated Drug Discovery Processes – Chemical synthesis, Purification, Analytical, Focused Libraries – SAR of Primary Assays, hERG, CYP Inhibition ¾ Pharmacology Know-how and Insights - SiNERG – Receptor Kinetics / Receptor Desensiti

  46. Slide 46: Research Targets

    Research Targets ¾ Drug discovery platform which integrates the fundamental principles perfected in GPCR pharmacology (kinetics, efficacy, and desensitization) to drive novel target drug discovery / SAR process. – Neurology (Pain, Epilepsy, Movement Disorders) – Metabolic disorders (Diabetes) – Psyc

  47. Slide 47: Financial Highlights

    Financial Highlights Year to Date Year Ending June 30, 2008 December 31, 2007 Revenues and $ 2.5 million $ 6.2 million other income Operating and other Expenses $ 44.5 million $ 213.5 million Net income (loss) $ (42.0) million $ (207.3) million Cash and short term $ 133.5 million $ 179.4 million Inv

Neurocrine Biosciences — Investor Presentation (September 2008) on 6ix